Polymeric nanoparticles and a process of preparation thereof
The present invention relates to the field of nanotechnology, in particular, to the production of biodegradable polymeric nanoparticles. The present invention provides a biodegradable polymeric nanoparticle made up of a block copolymer and a process for producing the same. The nanoparticles are produced without the use of any emulsifiers and have a size ranging from 30-120 nm. The methods of controlling the drug loading capacity are disclosed along with the process of producing entity-loaded nanoparticles. Compositions comprising the nanoparticles and their use in therapeutics, diagnostics and theranostics are also disclosed.
1. A biodegradable polymeric nanoparticle formed of a block copolymer comprising poly(lactic acid) (PLA) chemically modified with a hydrophilic-hydrophobic block copolymer, wherein said hydrophilic-hydrophobic block copolymer is selected from a block copolymer consisting essentially of poly(methyl methacrylate)-poly(methylacrylic acid) (PMMA-PMAA), poly(styrene-polyacrylic) acid(PS-PAA), poly(acrylic acid)-poly(vinylpyridine) (PAA-PVP), poly(acrylic acid)-poly(N,N-dimethylaminoethyl methacrylate) (PAA-PDMAEMA), poly(ethylene glycol)-poly(butylene glycol) (PEG-PBG), and poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) (PEG-PPG-PEG).
2. The biodegradable polymeric nanoparticle of claim 1 , wherein the biodegradable nanoparticle is formed of the tetra block copolymer PLA-PEG-PPG-PEG.
3. The biodegradable polymeric nanoparticle of claim 1 or 2 , wherein the PLA has an average molecular weight in the range of about 4,000 g/mol to 90,000 g/mol.
4. The biodegradable polymeric nanoparticle of claim 2 , wherein the PEG-PPG-PEG has an average molecular weight in the range of about 4,000 g/mol to 15,000 g/mol.
5. The biodegradable polymeric nanoparticle of claim 1 , wherein the biodegradable nanoparticle is formed of the penta block copolymer PLA-PEG-PPG-PEG-PLA.
6. The biodegradable polymeric nanoparticle of claim 1 , wherein the PLA is chemically modified with a hydrophilic-hydrophobic block copolymer using a covalent bond.
7. The biodegradable polymeric nanoparticle of claim 1 , wherein the size of the biodegradable polymeric nanoparticle is in the range of about 30 to 120 nm.
8. The biodegradable polymeric nanoparticle of claim 1 , wherein the biodegradable polymeric nanoparticle is substantially free of emulsifier.
9. The biodegradable polymeric nanoparticles of claim 1 , wherein the biodegradable polymeric nanoparticle further comprises emulsifier at a weight percentage from about 0.5% to 5%.
10. The biodegradable polymeric nanoparticle of claim 1 , wherein the average molecular weight of the PLA is in the range of 4,000 to 90,000 g/mol, the average molecular weight of the PEG-PPG-PEG is in the range of about 4,000 g/mol to 15,000 g/mol, and wherein the biodegradable polymeric nanoparticle further comprises emulsifier at a weight percentage from about 0.5% to 5%.
11. The biodegradable polymeric nanoparticle of claim 1 , wherein the average molecular weight of the PLA is less than or equal to about 16,000 g/mol, the average molecular weight of the PEG-PPG-PEG is in the range of about 4,000 g/mol to 15,000 g/mol, and wherein the composition is substantially free of emulsifier.
12. The biodegradable polymeric nanoparticle of claim 1 further comprising a therapeutic agent.
13. The biodegradable polymeric nanoparticle of claim 12 , wherein the therapeutic agent is encapsulated, surface conjugated, or adsorbed on the biodegradable polymeric nanoparticle.
14. The biodegradable polymeric nanoparticle of claim 13 , wherein the therapeutic agent is selected from a group comprising small organic molecules, nucleic acids, polynucleotides, oligonucleotides, nucleosides, DNA, RNA, amino acids, peptides, proteins, antibiotics, low molecular weight molecules, chemotherapeutics, drugs, metal ions, dyes, radioisotopes, contrast agents and imaging agents.
15. The biodegradable polymeric nanoparticle of claim 14 , wherein the peptide is an anti-cancer peptide.
16. The biodegradable polymeric nanoparticle of claim 14 , wherein the therapeutic agent is a chemotherapeutic.
17. The biodegradable polymeric nanoparticle of claim 16 , wherein the chemotherapeutic is selected from the group consisting of paclitaxel, doxorubicin, pimozide, perimethamine, indenoisoquinolines, or nor-indenoisoquinolines.
18. The biodegradable polymeric nanoparticle of claim 1 , further comprising a targeting moiety selected from the group consisting of vitamins, small molecule drugs, ligands, amines, peptide fragments, antibodies, and aptamers.